2nd Phase 3 Study of Low-dose Oral Treatment for Fibromyalgia Gets Underway
News
Tonix Pharmaceuticals announced that the first patient has been dosed in RE-AFFIRM, the company’s second Phase 3 clinical trial evaluating its cyclobenzaprine HCl sublingual tablets, known as TNX-102 SL, as a low-dose nighttime treatment for fibromyalgia. TNX-102 SL ... Read more